Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 293 results for breast cancer

  1. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  2. Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical outcomes in women who choose and women who do not choose to have risk-reducing surgery. [new 2013]

    Studies show that risk-reducing surgery significantly reduces risk of breast cancer, but there is insufficient evidence to decide...

    Research recommendation
    Published
    9 June 2015

  3. Neoadjuvant endocrine therapy in postmenopausal women:- Is there a benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer?

    for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To find out why...

    Research recommendation
    Published
    11 December 2018

  4. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA951

  5. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued

  6. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

    Technology appraisal guidance
    Discontinued

  8. Carrier probability calculation models:- Further research is recommended into developing and validating models for calculating carrier probability, which incorporate additional data, such as the molecular pathology of tumours and the prevalence of mutations in different ethnic groups. [new 2013]

    of mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated...

    Research recommendation
    Published
    9 June 2015

  9. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.

    Technology appraisal guidance
    Published
    28 October 2009
    View recommendations

    Sections for TA183

  10. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued [GID-TA10295]

    Technology appraisal guidance
    Discontinued

  11. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

    Technology appraisal guidance
    Discontinued

  12. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy TS ID 12119

    Awaiting development [GID-TA11658] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

    Technology appraisal guidance
    Discontinued

  14. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  15. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued [GID-TA10803]

    Technology appraisal guidance
    Discontinued